MAPT and Parkinson disease: Parnetti et al. (2019), in a multicenter observational study of 200 PD patients and 150 controls, supported the use of multi-biomarker panels, showing that a combination of α-synuclein, DJ-1, Tau, and NfL provided superior diagnostic accuracy.